Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience
Uterine sarcomas are rare and aggressive gynecological malignancies. We evaluated the epidemiology, treatment outcomes and survival rates in uterine sarcoma patients managed in our institute. The medical records of women with histology proven uterine sarcoma, including leiomyosarcoma (LMS), adenosar...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/12/9/200 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850261490822545408 |
|---|---|
| author | Aakriti Aggarwal Federico Ferrari Andreas Zouridis Sean Kehoe Sarah Pratap Elisa Gozzini Hooman Soleymani Majd |
| author_facet | Aakriti Aggarwal Federico Ferrari Andreas Zouridis Sean Kehoe Sarah Pratap Elisa Gozzini Hooman Soleymani Majd |
| author_sort | Aakriti Aggarwal |
| collection | DOAJ |
| description | Uterine sarcomas are rare and aggressive gynecological malignancies. We evaluated the epidemiology, treatment outcomes and survival rates in uterine sarcoma patients managed in our institute. The medical records of women with histology proven uterine sarcoma, including leiomyosarcoma (LMS), adenosarcoma (ADS), and endometrial stromal sarcoma (ESS), treated at our institution from February 2010 to February 2022, were analyzed. In total, 41 patients were identified. In detail, LMS, ADS, and high-grade and low-grade ESS were identified, respectively, in 60.9%, 19.5%, 12.1%, and 7.3% of the cases. The majority of women affected by LMS (72%) underwent primary surgery and 40% of them also received adjuvant chemotherapy. A surgical approach was the preferred mode of treatment in 83% of the recurrences. The median OS (overall survival), DFS (disease free survival), and PFS (progression free survival) for the LMS group were 25, 44.5, and 8 months, respectively. The 5-year survival rates for LMS, ADS, and ESS groups were 30.5%, 100% and 37.5%, respectively. The 5-year survival for LMS was found to be significantly worse than for other histology types (<i>p</i> = 0.016). Our study provides valuable data for the evaluation of treatment strategies and survival trends among these rare cancers. The management and follow-up planning of each subtype requires a thorough patient-focused multidisciplinary discussion. |
| format | Article |
| id | doaj-art-b1bff2a7bf374b2faa59ff8f7463daed |
| institution | OA Journals |
| issn | 2079-9721 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diseases |
| spelling | doaj-art-b1bff2a7bf374b2faa59ff8f7463daed2025-08-20T01:55:22ZengMDPI AGDiseases2079-97212024-09-0112920010.3390/diseases12090200Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford ExperienceAakriti Aggarwal0Federico Ferrari1Andreas Zouridis2Sean Kehoe3Sarah Pratap4Elisa Gozzini5Hooman Soleymani Majd6Department of Obstetrics and Gynecology, John Radcliffe Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 9DU, UKDepartment of Clinical and Experimental Sciences, Obstetrics and Gynecology, University of Brescia, 25100 Brescia, ItalyDepartment of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Clinical Oncology, Churchill Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Clinical and Experimental Sciences, Obstetrics and Gynecology, University of Brescia, 25100 Brescia, ItalyDepartment of Gynaecological Oncology, Churchill Hospital, Oxford University Hospitals, NHS Foundation Trust, Oxford OX3 7LE, UKUterine sarcomas are rare and aggressive gynecological malignancies. We evaluated the epidemiology, treatment outcomes and survival rates in uterine sarcoma patients managed in our institute. The medical records of women with histology proven uterine sarcoma, including leiomyosarcoma (LMS), adenosarcoma (ADS), and endometrial stromal sarcoma (ESS), treated at our institution from February 2010 to February 2022, were analyzed. In total, 41 patients were identified. In detail, LMS, ADS, and high-grade and low-grade ESS were identified, respectively, in 60.9%, 19.5%, 12.1%, and 7.3% of the cases. The majority of women affected by LMS (72%) underwent primary surgery and 40% of them also received adjuvant chemotherapy. A surgical approach was the preferred mode of treatment in 83% of the recurrences. The median OS (overall survival), DFS (disease free survival), and PFS (progression free survival) for the LMS group were 25, 44.5, and 8 months, respectively. The 5-year survival rates for LMS, ADS, and ESS groups were 30.5%, 100% and 37.5%, respectively. The 5-year survival for LMS was found to be significantly worse than for other histology types (<i>p</i> = 0.016). Our study provides valuable data for the evaluation of treatment strategies and survival trends among these rare cancers. The management and follow-up planning of each subtype requires a thorough patient-focused multidisciplinary discussion.https://www.mdpi.com/2079-9721/12/9/200uterine sarcomauterine leiomyosarcomaendometrial stromal sarcomaadenosarcomasarcomasurvival |
| spellingShingle | Aakriti Aggarwal Federico Ferrari Andreas Zouridis Sean Kehoe Sarah Pratap Elisa Gozzini Hooman Soleymani Majd Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience Diseases uterine sarcoma uterine leiomyosarcoma endometrial stromal sarcoma adenosarcoma sarcoma survival |
| title | Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience |
| title_full | Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience |
| title_fullStr | Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience |
| title_full_unstemmed | Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience |
| title_short | Survival Trends for Uterine Sarcomas from a Tertiary Center: The Oxford Experience |
| title_sort | survival trends for uterine sarcomas from a tertiary center the oxford experience |
| topic | uterine sarcoma uterine leiomyosarcoma endometrial stromal sarcoma adenosarcoma sarcoma survival |
| url | https://www.mdpi.com/2079-9721/12/9/200 |
| work_keys_str_mv | AT aakritiaggarwal survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience AT federicoferrari survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience AT andreaszouridis survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience AT seankehoe survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience AT sarahpratap survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience AT elisagozzini survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience AT hoomansoleymanimajd survivaltrendsforuterinesarcomasfromatertiarycentertheoxfordexperience |